Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
207 studies found for:    "PCI-32765"
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Condition: Recurrent Mature B-cell Neoplasms
Intervention: Drug: PCI-32765
2 Active, not recruiting Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Condition: Leukemia
Interventions: Other: Heavy Water (2H2O);   Drug: PCI-32765
3 Completed Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Conditions: B-Cell Lymphoma;   B-Cell Leukemia
Intervention: Drug: PCI-32765
4 Completed A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
5 Active, not recruiting Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: PCI-32765
6 Completed A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
Condition: Healthy Participants
Interventions: Drug: PCI-32765;   Drug: Rifampin
7 Enrolling by invitation A Long-term Extension Study of PCI-32765 (Ibrutinib)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
8 Completed
Has Results
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
9 Completed A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: PCI-32765
10 Enrolling by invitation Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Diffuse Well-differentiated Lymphocytic Lymphoma;   B Cell Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin's Lymphoma;   Waldenstrom Macroglobulinemia;   Burkitt Lymphoma;   B-Cell Diffuse Lymphoma
Intervention: Drug: PCI-32765
11 Completed A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Condition: Healthy Participants
Intervention: Drug: Ibrutinib
12 Completed
Has Results
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Intervention: Drug: PCI-32765
13 Completed
Has Results
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell B-lymphoma
Intervention: Drug: ibrutinib
14 Completed A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
Condition: Healthy Volunteer
Interventions: Drug: Treatment A: PCI-32765;   Drug: Treatment B: PCI-32765
15 Active, not recruiting Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: PCI-32765
16 Completed
Has Results
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
17 Active, not recruiting A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: Ibrutinib
18 Recruiting A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
19 Recruiting A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Condition: Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
20 Completed
Has Results
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Prolymphocyctic Leukemia;   Richter's Transformation
Interventions: Drug: PCI-32765;   Drug: ofatumumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.